Article
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
Antimicrobial agents and chemotherapy - 1 Jan 2010
Delelis Olivier, Thierry Sylvain, Subra Frédéric, Simon Françoise, Malet Isabelle, Alloui Chakib, Sayon Sophie, Calvez Vincent, Deprez Eric, Marcelin Anne-Geneviève, Tchertanov Luba, Mouscadet Jean-François
Abstract excerpt
Integrase (IN), the HIV-1 enzyme responsible for the integration of the viral genome into the chromosomes of infected cells, is the target of the recently approved antiviral raltegravir (RAL). Despite this drug's activity against viruses resistant to other antiretrovirals, failures of raltegravir therapy were observed, in association with the emergence of resistance due to mutations in the integrase coding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.